Divestments hurt Moberg
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Offloading a number of ‘non-core’ brands left turnover at Moberg Pharma down by 12% to SEK91.5 million (€8.9 million) in the first-quarter of 2018.